## Regulatory event that de-risks the growth narrative (and tightens the timeline) Vanda disclosed that the FDA has **approved BYSANTI (milsaperidone) tablets** as a **first-line therapy** for (i) the **acute treatment of manic or mixed episodes associated with bipolar I disorder** and (ii) the **treatment of schizophrenia** in adults. ["has approved BYSANTI"](0001628280-26-010376|1) ["acute treatment of manic or mixed episodes"](0001628280-26-010376|1) ["treatment of schizophrenia"](0001628280-26-010376|1) Importantly for investors, management is already anchoring execution expectations around a **U.S. commercial availability/launch window in Q3 2026**, which effectively turns this from a “someday” pipeline story into a dated operational build. ["commercial availability of BYSANTI in Q3 of 2026"](0001628280-26-010376|1) ## “New Chemical Entity” — but built to commercialize like a franchise extension The disclosure positions BYSANTI as a **new chemical entity (NCE)** while emphasizing that it **leverages an existing clinical and real-world evidence base**: Vanda states BYSANTI showed **bioequivalence to iloperidone** and can draw on “more than **100,000 patient-years** of real-world experience” with Fanapt (iloperidone). ["new chemical entity (NCE)"](0001628280-26-010376|1) ["bioequivalence to iloperidone"](0001628280-26-010376|1) ["more than 100,000 patient-years"](0001628280-26-010376|1) **Alpha between the lines:** this framing reads like a deliberate attempt to position BYSANTI as *commercially scalable*—not a cold-start launch—by tying it to a prescriber-accessible “heritage” molecule and an established psychiatry footprint. ["leverage well-established knowledge"](0001628280-26-010376|1) ## A built-in platform play: two indications now, additional shots already running Vanda also disclosed BYSANTI is **currently being tested** as a **once-daily adjunctive treatment** in **treatment-resistant major depressive disorder (MDD)**, with the study expected to complete by year-end (per the Feb. 20, 2026 disclosure). ["once-daily adjunctive treatment"](0001628280-26-010376|1) ["expected to complete by the end of this year"](0001628280-26-010376|1) And in its most recent annual report (filed shortly before the approval disclosure), Vanda described the BYSANTI NDA pathway (FDA acceptance and PDUFA timing) and separately noted its Phase III MDD study timeline. ["FDA accepted our New Drug Application"](0001628280-26-007460|0) ["PDUFA target action date"](0001628280-26-007460|0) ["Phase III clinical study"](0001628280-26-007460|0) ## The underappreciated asset: longevity of exclusivity and IP runway Vanda’s approval-related disclosure explicitly points to **regulatory data exclusivity and issued U.S. patents**, with the **latest expiring in 2044**. ["marketing exclusivity is expected"](0001628280-26-010376|1) ["latest expiring in 2044"](0001628280-26-010376|1) **Alpha between the lines:** if Vanda executes competently in 2026, the company is signaling not just a launch, but the potential to compound value over a long duration—critical in CNS where durable brands and lifecycle strategies can matter as much as peak-year curves. ["robust foundation for long-term"](0001628280-26-010376|1) ## Why Q3’26 matters: it’s a catalyst for the *commercial engine*, not just the pipeline In Vanda’s most recent 10-K, the company frames its business model around **development and commercialization** and highlights Fanapt as part of its commercial portfolio. ["focused on the development and commercialization"](0001628280-26-007460|0) ["commercial portfolio is currently comprised"](0001628280-26-007460|0) The BYSANTI approval + dated launch window effectively shifts investor focus from “will it be approved?” to “how efficiently can the company translate an approval into prescribing behavior and payer access”—the part of the story where durable alpha is usually created (or lost). ["anticipates commercial availability"](0001628280-26-010376|1)

## Regulatory event that de-risks the growth narrative (and tightens the timeline) Vanda disclosed that the FDA has **approved BYSANTI (milsaperidone) tablets** as a **first-line therapy** for (i) the **acute treatment of manic or mixed episodes associated with bipolar I disorder** and (ii) the **treatment of schizophrenia** in adults. ["has approved BYSANTI"](0001628280-26-010376|1) ["acute treatment of manic or mixed episodes"](0001628280-26-010376|1) ["treatment of schizophrenia"](0001628280-26-010376|1) Importantly for investors, management is already anchoring execution expectations around a **U.S. commercial availability/launch window in Q3 2026**, which effectively turns this from a “someday” pipeline story into a dated operational build. ["commercial availability of BYSANTI in Q3 of 2026"](0001628280-26-010376|1) ## “New Chemical Entity” — but built to commercialize like a franchise extension The disclosure positions BYSANTI as a **new chemical entity (NCE)** while emphasizing that it **leverages an existing clinical and real-world evidence base**: Vanda states BYSANTI showed **bioequivalence to iloperidone** and can draw on “more than **100,000 patient-years** of real-world experience” with Fanapt (iloperidone). ["new chemical entity (NCE)"](0001628280-26-010376|1) ["bioequivalence to iloperidone"](0001628280-26-010376|1) ["more than 100,000 patient-years"](0001628280-26-010376|1) **Alpha between the lines:** this framing reads like a deliberate attempt to position BYSANTI as *commercially scalable*—not a cold-start launch—by tying it to a prescriber-accessible “heritage” molecule and an established psychiatry footprint. ["leverage well-established knowledge"](0001628280-26-010376|1) ## A built-in platform play: two indications now, additional shots already running Vanda also disclosed BYSANTI is **currently being tested** as a **once-daily adjunctive treatment** in **treatment-resistant major depressive disorder (MDD)**, with the study expected to complete by year-end (per the Feb. 20, 2026 disclosure). ["once-daily adjunctive treatment"](0001628280-26-010376|1) ["expected to complete by the end of this year"](0001628280-26-010376|1) And in its most recent annual report (filed shortly before the approval disclosure), Vanda described the BYSANTI NDA pathway (FDA acceptance and PDUFA timing) and separately noted its Phase III MDD study timeline. ["FDA accepted our New Drug Application"](0001628280-26-007460|0) ["PDUFA target action date"](0001628280-26-007460|0) ["Phase III clinical study"](0001628280-26-007460|0) ## The underappreciated asset: longevity of exclusivity and IP runway Vanda’s approval-related disclosure explicitly points to **regulatory data exclusivity and issued U.S. patents**, with the **latest expiring in 2044**. ["marketing exclusivity is expected"](0001628280-26-010376|1) ["latest expiring in 2044"](0001628280-26-010376|1) **Alpha between the lines:** if Vanda executes competently in 2026, the company is signaling not just a launch, but the potential to compound value over a long duration—critical in CNS where durable brands and lifecycle strategies can matter as much as peak-year curves. ["robust foundation for long-term"](0001628280-26-010376|1) ## Why Q3’26 matters: it’s a catalyst for the *commercial engine*, not just the pipeline In Vanda’s most recent 10-K, the company frames its business model around **development and commercialization** and highlights Fanapt as part of its commercial portfolio. ["focused on the development and commercialization"](0001628280-26-007460|0) ["commercial portfolio is currently comprised"](0001628280-26-007460|0) The BYSANTI approval + dated launch window effectively shifts investor focus from “will it be approved?” to “how efficiently can the company translate an approval into prescribing behavior and payer access”—the part of the story where durable alpha is usually created (or lost). ["anticipates commercial availability"](0001628280-26-010376|1)